Salute e Benessere

Appointment of Silvère Lucquin as Chief Executive Officer of Okomera

Prior to Ganymed, Silvère held key positions at Aditlys Medical, where he oversaw the company's spin-off and early structuring, and at CorWave, where he was the first employee, leading major development activities and contributing to its growth through two fundraising rounds (series A and B). Prior to Ganymed, Silvère held key positions at Aditlys Medical, where he oversaw the company's spin-off and early structuring, and at CorWave, where he was the first employee, leading major development...
PR Newswire
09/09/2025

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with…

Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular diseasePacibekitug is a promising targeted therapy with the potential to reduce systemic inflammation—an independent and significant driver of cardiovascular risk—addressing a critical unmet need in ASCVD treatment Offer price of USD 48 per share valuing the company at approximately USD 1.4bn on a fully diluted basis...
Nasdaq GlobeNewswire
09/09/2025

Elevating Healthcare Innovation: ICP DAS-BMP Brings Advanced TPU Portfolio at…

ICP DAS-BMP will also showcase a wide selection of TPU materials for diverse medical applications. The basic Arothane™, Alithane™, and Durathane™ TPUs (ARP/ALP/ALC series) meet the requirements for most body-contact medical devices, especially barium sulfate-containing grades such as B20 or B40. The Arothane™ ARP-B20 and Durathane™ ALC-B40 have passed the ISO 10993-6 13-week implantation test, making them suitable for implantation up to 90 days. Excellent dispersibility and biological safety…
PR Newswire
09/09/2025

Amorepacific Group Marks 80th Anniversary: Unveils New Vision Slogan "Create New…

Experience the full interactive Multichannel News Release here: https://www.multivu.com/amorepacific/9352251-en-amorepacific-celebrates-its-80th-anniversary Experience the full interactive Multichannel News Release here:https://www.multivu.com/amorepacific/9352251-en-amorepacific-celebrates-its-80th-anniversary Under the new vision slogan "Create New Beauty," the Amorepacific group established five strategic pillars to bring the vision to life. The company will strengthen its…
PR Newswire
09/09/2025

Asthma Market to Show Paltry Growth at a CAGR of 1.95% During the Forecast…

Asthma Market Summary Asthma Market Summary Discover the new asthma treatment @Asthma Treatment Market Key Factors Driving the Growth of the Asthma Market Rising Prevalence of Asthma Driving the Market Asthma affects millions worldwide, and its prevalence continues to increase due to urbanization, environmental pollution, changing lifestyles, and higher exposure to allergens. According to DelveInsight analysis, the total number of diagnosed prevalent asthma cases is...
PR Newswire
08/09/2025

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

Leuven, BELGIUM – September 8, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notification as follows: Oxurion received a transparency notification on September 3, 2025, from Atlas…
Actusnews Wire
08/09/2025

OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of…

OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025NANTES, France, September 8, 2025, 6p.m. CET – OSE Immunotherapeutics SA(ISIN: FR0012127173; Mnemo: OSE) announces that, following today’s hearing before the Nantes Commercial Court under the accelerated procedure (procédure dite “à bref délai”), the Court has taken under advisement the matter concerning the regularity of the declaration of the concerted...
Nasdaq GlobeNewswire
08/09/2025

Press Release : Sequana Medical Announces New Share Capital Amount and New…

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNTAND NEW NUMBER OF SHARES Ghent, Belgium, 8 September 2025 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that, as a result of a subscription to new shares by GEM Global Yield LLC SCS (" GEM "), the Company's share capital has increased on 8 September 2025 from…
Nasdaq GlobeNewswire
08/09/2025

Idorsia highlights very low real-world abuse potential of DORA class for…

Analysis of the FAERS database shows that the real-world abuse potential of the DORA class is very low and markedly less than those seen for other scheduled and non-scheduled insomnia therapiesAllschwil, Switzerland – September 8, 2025Idorsia Ltd (SIX: IDIA) presented real-world data from the FDA Adverse Event Reporting System (FAERS) at the World Sleep 2025, evaluating abuse-related adverse events for dual orexin receptor antagonists (DORAs) in comparison to other insomnia therapies...
Nasdaq GlobeNewswire
08/09/2025

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers…

PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients withextensive-stage small cell lung cancer (”ES-SCLC”) ,expanding evidence for its potential to set a new standard of care in first-line ES-SCLC and beyondGlobal interim Phase 2 data showed a 76.3% confirmed objective response rate (cORR), 100% disease control rate (DCR), a median progression free survival (mPFS) of 6.8 months and a manageable...
Nasdaq GlobeNewswire
08/09/2025

Wearable Healthcare Devices Market worth US$75.98 billion by 2030 with 10.9%…

Browse in-depth TOC on "Wearable Healthcare Devices Market" Browse in-depth TOC on "Wearable Healthcare Devices Market" 430 - Tables 50 - Figures 352 - Pages By product,the wearable healthcare devices market is segmented into trackers, smartwatches, patches, and smart clothing. In 2024, smartwatches emerged as the fastest-growing product segment, driven by their expanding range of health-focused features, seamless integration with digital ecosystems, and increasing user...
PR Newswire
08/09/2025

Food Supplement Market to Hit $345.13 Billion by 2031, Fueled by Preventive…

By Ingredient By Ingredient In 2024, the vitamins category commanded a dominant share, estimated at approximately37.5% of theU.S. food supplements market . Botanical extracts, minerals, and omega fatty acids maintained strong positions-especially in cardiovascular, cognitive, and anti-aging applications. Proteins and amino acids saw accelerated adoption in fitness and sports nutrition sectors, while emerging niches like plant-based and clean-label ingredients expanded rapidly...
PR Newswire
08/09/2025

Disposable Medical Device Market worth US$144.85 billion by 2030 with 4.9% CAGR…

Browse in-depth TOC on "Disposable Medical Device Market" Browse in-depth TOC on "Disposable Medical Device Market" 100 - Tables 80 - Figures 200 - Pages By device type,the adoption of drug delivery devices is driven by the increasing prevalence of chronic diseases, such as diabetes, asthma, and cardiovascular conditions, which require regular and precise medication administration. Devices like disposable syringes, insulin pens, auto-injectors, inhalers, and transdermal...
PR Newswire
08/09/2025

Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape…

Industry analysts expect the antibody-drug conjugate market to reach $50 billion by 2030[3], driven by 16 approved therapies and accelerating clinical pipelines. Immuno-oncology revenues jumped from $94 billion to $109.39 billion in 2025 alone[4], as leading institutions recognize the transformative potential of precision-targeted therapies and combination treatment approaches for previously untreatable cancers. Industry analysts expect the antibody-drug conjugate market to reach$50 billion...
PR Newswire
08/09/2025

Sirtex Receives Expanded CE Mark Approval for SIR-Spheres® Y-90 Resin…

"This milestone is about more than regulatory approval—it's about giving hope and options back to patients facing some of the toughest cancer diagnoses," said Matt Schmidt, CEO of Sirtex Medical. "By expanding access to SIR-Spheres®, we're ensuring that more people can benefit from a well-tolerated therapy when they need it most." "This milestone is about more than regulatory approval—it's about giving hope and options back to patients facing some of the toughest cancer…
PR Newswire
08/09/2025

Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar

Dr. Sinkule will be available to meet with investors and potential partners during the conference. Interested parties can contact [email protected]. Dr. Sinkule will be available to meet with investors and potential partners during the conference. Interested parties can contact [email protected]. About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies...
PR Newswire
08/09/2025

Doja Cat Takes a Bite Out of M•A•C Cosmetics at 2025 VMAs

Doja made her official M•A•C debut at the 2025 MTV Video Music Awards, shocking the red carpet when she appeared to take a bite out of a M•A•C Lipstick in her go-to shade Lady Danger – which, in true Doja fashion, turned out to be an edible chocolate replica created by world-renowned pastry chef Amaury Guichon. She then opened the show with the debut performance of "Jealous Type" and later took home the 2025 Best K-Pop VMA for LISA ft. Doja Cat & RAYE's "Born Again. Doja made…
PR Newswire
08/09/2025

AMO Pharma Enters into License Agreement with Population Health Research…

"AMO Pharma is committed to advancing and supporting research that can lead to new first-in-class disease-modifying therapies for serious, life-threatening conditions such as ARVC," said Mike Snape, Chief Scientific Officer at AMO Pharma. "The recent publication in JACC: Basic to Translational Science reinforces the growing body of evidence supporting glycogen synthase kinase-3 beta (GSK3β) inhibition as a potential treatment strategy for ARVC and the broader ACM spectrum, which…
PR Newswire
08/09/2025

Transcatheter Aortic Valve Replacement (TAVR) Market to Reach USD 14.06 Billion…

TAVR is a minimally invasive procedure that replaces the aortic valve using a catheter-based approach, eliminating the need for open-heart surgery. Initially approved for high-risk patients, TAVR is now rapidly expanding to intermediate- and low-risk groups due to strong clinical outcomes and device innovation. TAVR is a minimally invasive procedure that replaces the aortic valve using a catheter-based approach, eliminating the need for open-heart surgery. Initially approved for high-risk...
PR Newswire
08/09/2025

FDA Accepts Letter of Intent to Qualify LSM by VCTE (FibroScan®) as First…

This is the first time the FDA is accepting the initiation of the qualification process of a non-invasive test as a reasonably likely surrogate endpoint in drug development for MASH—a progressive, advanced form of steatotic liver disease that can lead to cirrhosis, liver cancer, transplantation, or death. In a communication issued by the FDA, Frank Anania, MD, director of the Division of Hepatology and Nutrition in CDER, stated, "This proposal represents an important step toward adopting…
PR Newswire
08/09/2025

Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of…

– Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m. ET – – Company to Host Investor Webcast onMonday, Sept. 8at8:00 a.m. ET– DUBLIN , Sept. 8, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced detailed positive results from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1). Alixorexton, formerly ALKS 2680, is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in phase 2...
PR Newswire
08/09/2025

ToolGen Files Patent Infringement Lawsuit Against Lonza in the Netherlands

CASGEVY, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, is the world's first gene-editing therapy approved for sickle cell disease and beta-thalassemia. It has been authorized in the United Kingdom, United States, and European Union. Under a long-term supply agreement with Vertex, Lonza manufactures CASGEVY at its Netherlands site. CASGEVY, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, is the world's first gene-editing therapy approved for sickle cell disease and...
PR Newswire
08/09/2025

ONWARD Medical Receives CE Mark for ARC-EX, Enabling Commercial Launch of…

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)The CE Mark certification allows marketing for both clinic and home useFirst commercial sales of the ARC-EX ®System in Europe are expected in Q4 2025The CE Mark enables commercialization in the European Union and facilitates a streamlined regulatory pathway in other countries, including in the UK and Switzerland EINDHOVEN, the Netherlands, Sept...
Nasdaq GlobeNewswire
08/09/2025

Newronika Appoints Keith Carlton as Executive Chairman to Reinforce Strategic…

"We are honored to welcome Keith as our Executive Chairman," said Lorenzo Rossi, PhD, Co-Founder and CEO of Newronika. "His strategic vision, coupled with a distinguished record of scaling innovative medical technology companies, will be pivotal as we advance the clinical validation and to the commercialization of AlphaDBS, our proprietary adaptive deep brain stimulation system. This innovative platform is designed to deliver precision therapy that enhances symptom relief and…
PR Newswire
08/09/2025
Altri  Comunicati